For example, the detailed mode of action of the CD30 antibody-drug conjugate Brentuximab vedotin in DLBCL is not well understood since the clinical outcome seems to be partially independent of the CD30 expression on the tumor cells. Here, TNFRSF8 is linked to diffuse large B-cell lymphoma.